Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients
- Author
- ANDERSON, R. D1 ; GRIFFY, K. G; JUNG, D; DORR, A; HULSE, J. D; SMITH, R. B1
[1] Novum, Inc., Pittsburgh PA 15206, United States - Source
Clinical therapeutics. 1995, Vol 17, Num 3, pp 425-432 ; ref : 9 ref
- ISSN
- 0149-2918
- Scientific domain
- Pharmacology drugs
- Publisher
- Excerpta Medica, Belle Mead, NJ
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Antiviral Biodisponibilité Cytomegalovirus humain Etude comparative Ganciclovir Homme Nucléoside acyclique Pharmacocinétique Purine nucléoside Rythme administration SIDA Séropositivité Virus immunodéficience humaine Voie intraveineuse Voie orale Betaherpesvirinae Herpesviridae Immunodéficit Immunopathologie Infection Lentivirinae Retroviridae Virose Virus
- Keyword (en)
- Antiviral Bioavailability Human cytomegalovirus Comparative study Human Acyclic nucleoside Pharmacokinetics Purine nucleoside Administration schedule AIDS Seropositivity Human immunodeficiency virus Intravenous administration Oral administration Betaherpesvirinae Herpesviridae Immune deficiency Immunopathology Infection Lentivirinae Retroviridae Viral disease Virus
- Keyword (es)
- Antiviral Biodisponibilidad Human cytomegalovirus Estudio comparativo Hombre Nucleósido acíclico Farmacocinética Purina nucleósido Ritmo administración SIDA Seropositividad Human immunodeficiency virus Vía intravenosa Vía oral Betaherpesvirinae Herpesviridae Inmunodeficiencia Inmunopatología Infección Lentivirinae Retroviridae Virosis Virus
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02S Antibiotics. Antiinfectious agents. Antiparasitic agents / 002B02S05 Antiviral agents
- Discipline
- Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 3602476
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1016/0149-2918(95)80107-3 
https://dx.doi.org/10.1016/0149-2918(95)80107-3
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1016\/0149-2918(95)80107-3\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:204:\"Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg\/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients\";s:9:\"\u0000*\u0000jtitle\";s:21:\"Clinical therapeutics\";s:9:\"\u0000*\u0000stitle\";s:10:\"Clin. ther\";s:7:\"\u0000*\u0000date\";s:4:\"1995\";s:9:\"\u0000*\u0000volume\";s:2:\"17\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"425\";s:8:\"\u0000*\u0000epage\";s:3:\"432\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0149-2918\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"ANDERSON\";s:10:\"\u0000*\u0000aufirst\";s:4:\"R. D\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:12:\"GRIFFY, K. G\";i:1;s:7:\"JUNG, D\";i:2;s:7:\"DORR, A\";i:3;s:11:\"HULSE, J. D\";i:4;s:11:\"SMITH, R. B\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:204:\"Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg\/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients\";s:8:\"\u0000*\u0000place\";s:14:\"Belle Mead, NJ\";s:6:\"\u0000*\u0000pub\";s:15:\"Excerpta Medica\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1016\/0149-2918(95)80107-3\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:204:\"Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg\/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients\";s:9:\"\u0000*\u0000jtitle\";s:21:\"Clinical therapeutics\";s:9:\"\u0000*\u0000stitle\";s:10:\"Clin. ther\";s:7:\"\u0000*\u0000date\";s:4:\"1995\";s:9:\"\u0000*\u0000volume\";s:2:\"17\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"425\";s:8:\"\u0000*\u0000epage\";s:3:\"432\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0149-2918\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"ANDERSON\";s:10:\"\u0000*\u0000aufirst\";s:4:\"R. D\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:12:\"GRIFFY, K. G\";i:1;s:7:\"JUNG, D\";i:2;s:7:\"DORR, A\";i:3;s:11:\"HULSE, J. D\";i:4;s:11:\"SMITH, R. B\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:204:\"Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg\/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients\";s:8:\"\u0000*\u0000place\";s:14:\"Belle Mead, NJ\";s:6:\"\u0000*\u0000pub\";s:15:\"Excerpta Medica\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:28:\"10.1016\/0149-2918(95)80107-3\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1016\/0149-2918(95)80107-3\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:204:\"Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg\/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients\";s:9:\"\u0000*\u0000jtitle\";s:21:\"Clinical therapeutics\";s:9:\"\u0000*\u0000stitle\";s:10:\"Clin. ther\";s:7:\"\u0000*\u0000date\";s:4:\"1995\";s:9:\"\u0000*\u0000volume\";s:2:\"17\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"425\";s:8:\"\u0000*\u0000epage\";s:3:\"432\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0149-2918\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"ANDERSON\";s:10:\"\u0000*\u0000aufirst\";s:4:\"R. D\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:12:\"GRIFFY, K. G\";i:1;s:7:\"JUNG, D\";i:2;s:7:\"DORR, A\";i:3;s:11:\"HULSE, J. D\";i:4;s:11:\"SMITH, R. B\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:204:\"Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg\/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients\";s:8:\"\u0000*\u0000place\";s:14:\"Belle Mead, NJ\";s:6:\"\u0000*\u0000pub\";s:15:\"Excerpta Medica\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1016\/0149-2918(95)80107-3\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:204:\"Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg\/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients\";s:9:\"\u0000*\u0000jtitle\";s:21:\"Clinical therapeutics\";s:9:\"\u0000*\u0000stitle\";s:10:\"Clin. ther\";s:7:\"\u0000*\u0000date\";s:4:\"1995\";s:9:\"\u0000*\u0000volume\";s:2:\"17\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"425\";s:8:\"\u0000*\u0000epage\";s:3:\"432\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0149-2918\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"ANDERSON\";s:10:\"\u0000*\u0000aufirst\";s:4:\"R. D\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:12:\"GRIFFY, K. G\";i:1;s:7:\"JUNG, D\";i:2;s:7:\"DORR, A\";i:3;s:11:\"HULSE, J. D\";i:4;s:11:\"SMITH, R. B\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:204:\"Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg\/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients\";s:8:\"\u0000*\u0000place\";s:14:\"Belle Mead, NJ\";s:6:\"\u0000*\u0000pub\";s:15:\"Excerpta Medica\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1016\/0149-2918(95)80107-3\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:204:\"Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg\/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients\";s:9:\"\u0000*\u0000jtitle\";s:21:\"Clinical therapeutics\";s:9:\"\u0000*\u0000stitle\";s:10:\"Clin. ther\";s:7:\"\u0000*\u0000date\";s:4:\"1995\";s:9:\"\u0000*\u0000volume\";s:2:\"17\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"425\";s:8:\"\u0000*\u0000epage\";s:3:\"432\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0149-2918\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"ANDERSON\";s:10:\"\u0000*\u0000aufirst\";s:4:\"R. D\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:12:\"GRIFFY, K. G\";i:1;s:7:\"JUNG, D\";i:2;s:7:\"DORR, A\";i:3;s:11:\"HULSE, J. D\";i:4;s:11:\"SMITH, R. B\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:204:\"Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg\/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients\";s:8:\"\u0000*\u0000place\";s:14:\"Belle Mead, NJ\";s:6:\"\u0000*\u0000pub\";s:15:\"Excerpta Medica\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
